BTIG Research Reiterates Buy Rating for AC Immune (NASDAQ:ACIU)

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating reissued by stock analysts at BTIG Research in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $8.00 price target on the stock. BTIG Research’s price target would suggest a potential upside of 200.75% from the stock’s previous close.

Several other research analysts have also commented on ACIU. HC Wainwright reissued a “buy” rating on shares of AC Immune in a research report on Monday, August 24th. Weiss Ratings reissued a “sell (e+)” rating on shares of AC Immune in a research report on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $7.50.

AC Immune Stock Down 6.0%

NASDAQ:ACIU traded down $0.17 during mid-day trading on Wednesday, hitting $2.66. The company had a trading volume of 265,286 shares, compared to its average volume of 274,894. The business has a fifty day simple moving average of $2.55 and a 200-day simple moving average of $2.68. The company has a current ratio of 0.93, a quick ratio of 1.02 and a debt-to-equity ratio of 0.11. AC Immune has a 1 year low of $2.10 and a 1 year high of $4.00. The firm has a market capitalization of $270.71 million, a price-to-earnings ratio of -4.93 and a beta of 1.60.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.13. AC Immune had a negative return on equity of 100.17% and a negative net margin of 245.32%.The company had revenue of $18.67 million for the quarter, compared to analyst estimates of $9.59 million. Equities analysts forecast that AC Immune will post -0.6 earnings per share for the current fiscal year.

Institutional Trading of AC Immune

Large investors have recently modified their holdings of the business. Arrowstreet Capital Limited Partnership grew its stake in shares of AC Immune by 8.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock valued at $1,116,000 after acquiring an additional 30,035 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in AC Immune by 82.8% in the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock valued at $1,071,000 after acquiring an additional 176,701 shares during the period. Finally, AXQ Capital LP acquired a new position in AC Immune in the second quarter valued at approximately $25,000. 51.36% of the stock is currently owned by institutional investors and hedge funds.

More AC Immune News

Here are the key news stories impacting AC Immune this week:

• Positive Sentiment: AC Immune said ACI-7104 met all primary endpoints in Part 1 of the Phase 2 trial. The drug was generally safe and well tolerated, produced a 100% antibody response after three immunizations, and demonstrated antibody penetration into cerebrospinal fluid and signals of target engagement. AC Immune Reports Positive Safety and Immunogenicity at Week 100
• Positive Sentiment: The durable immunogenicity and cerebrospinal-fluid antibody findings strengthen the case that ACI-7104 can engage its intended target in the central nervous system. Part 2 of VacSYn is intended to assess clinical activity and help determine whether the program advances toward Phase 3. AC Immune Says ACI-7104 Shows Durable Immunogenicity
• Positive Sentiment: Analyst support increased the bullish tone: BTIG reaffirmed a Buy rating with an $8 price target, while H.C. Wainwright maintained its Buy rating and $12 target. These targets imply substantial upside if the clinical program continues to validate AC Immune’s platform. H.C. Wainwright Maintains Buy Rating
• Neutral Sentiment: Management plans discussions with the FDA regarding ACI-7104’s future development path in early 2027. Those talks could clarify the regulatory and Phase 3 requirements, but they are still several months away.
• Negative Sentiment: The reported results primarily demonstrate safety, immunogenicity and target engagement—not that ACI-7104 improves Parkinson’s symptoms or slows disease progression. Investors must still await clinical-activity data from Part 2, leaving considerable trial, regulatory and financing risk for the clinical-stage company.

AC Immune Company Profile

AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. Founded in 2003, the company develops precision medicines and diagnostic products designed to prevent, diagnose and treat neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and other conditions associated with misfolded proteins.

AC Immune’s research is based on its SupraAntigen and Morphomer technology platforms, which are intended to identify disease-related proteins and generate therapies or diagnostic tools that target them.